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1. Introduction 
The understanding of the interaction between Polidocanol (POL) and the target veins 
tissues is important in utilizing it in varicose veins diseases treatment. Generally, the 
development of new drug delivery routes may represent methods to improve the efficacy 
and/or safety of the active pharmaceutical ingredients. With this respect, the treatment 
involving POL administration as foam has gained widespread use (Cavezzi and Tessari, 
2009). Although the main approach in the treatment of small diameter veins, in 
venulectasias and reticular veins of less than 4 mm in diameter (class I/II and III) is 
sclerotherapy (Alos et al., 2006; Nijsten et. al., 2009; Parsi et al., 2007; Railan et al., 2006), 
lasers, especially the Nd:YAG laser, have shown interesting and non-negligible 
capabilities in treating these cases (Redondo and Cabrera, 2005; Santos et al., 2008; Trelles 
et al., 2005). Clinical experimental results prove that the exposure of the tissues 
impregnated with POL to laser radiation emitted at 1.06 Ǎm improves the efficiency of the 
treatment (Moreno Moraga, n.d.).  
The aim of this chapter is to present an extensive study concerning the optical properties of 
commercially available Polidocanol (Aethoxysklerol 2%, Kreussler & Co. GmbH, Germany) 
and the possible modifications induced at molecular level in this medicine as supplied by 
the manufacturer, by exposing it to Nd:YAG laser radiation.  
Almost 60% of the adult population of Europe and the USA present varicose or spider veins 
in the lower limbs and this is the seventh most common chronic vascular disorder, nine 
times more frequent than arterial diseases (Tibbs, 1997). In recent years, a significant, 
growing number of patients are consulting in order to correct the symptoms originated in 
this vascular disorder, as well as the aesthetic implications that cause this ailment. 
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The lower extremities contain both superficial and deep veins. The superficial venous 
system consists of the greater saphenous vein draining most of the leg, the lesser saphenous 
vein draining the posterior and lateral lower leg, and the lateral (subdermal) venous system 
draining the lateral leg above and below the knee. Clinically, this last system may be 
observed as visible veins. Dilatations of the most superficial veins are called telangiectasias. 
These are usually bright red and measure 0.03 mm to 0.3 mm in diameter. Slightly larger are 
postcapillary venulectasias, which measure 0.4 mm to 2 mm, and may be red or blue 
depending on their oxygenation. Telangiectasias and venulectasias are commonly referred 
to as spider veins. These connect to larger reticular veins measuring 2 mm to 4 mm that are 
typically blue because of the Tyndall effect and their deeper location within the dermis 
(Kunishige et al., 2007). 
The treatment of varicose veins reduces the symptoms and the complication rate of venous 
insufficiency and increases the patient’s health related quality of life. It can roughly be 
divided into four groups: compression therapy, surgical treatment, sclerotherapy and 
endovenous thermal ablation. To improve efficacy and treatment satisfaction and to reduce 
serious side effects, costs, and postoperative pain, new minimally invasive techniques, such 
as ultrasound-guided foam sclerotherapy (UGFS), endovenous laser therapy (EVLT), and 
radiofrequency ablation (RFA), have been introduced in the last decade (Nijsten et. al., 
2009). Also, sclerotherapy (mainly foam sclerotherapy) combined with 1.06 µm Nd:YAG 
laser beam therapy showed very encouraging clinical results. This new approach is ideal for 
treating varicose veins originating in the lateral subdermal plexus of the lower limbs or 
reticular veins of other locations. Veins of up to 4 mm calibre located at a depth between 2 
mm and  4 mm can be treated. Telangiectasias or spider-veins, located between 1.2 mm and 
1.7 mm below the surface of the skin, either associated with or independent from reticular 
veins in any location are also ideal for combined treatment. Surgery or EVLT continue to be 
recommended for the great saphenous veins (GSV) of a calibre greater than 8 mm. It is 
possible to treat truncal veins with combined POL and laser, but this requires particular 
expertise. In these cases ultrasound monitoring is well advised, both when puncturing and 
injecting the microfoam. When POL enters the veins it is detected by the ultrasound, so vein 
spasms, which occur after the injection, can be well controlled as well as their duration 
(Moreno Moraga, n.d.; Trelles et al., 2011). 
Sclerotherapy is the targeted elimination of varicose veins by injection of a sclerosing 
substance into the vein lumen. Sclerosing agents cause a chemical irritation of the venous 
intimate that produces an inflammation of the endothelial lining of the vessel. 
Subsequently, a secondary, wall-attached local thrombus is generated and, in long term, 
the vein will be transformed into a fibrous cord (Redondo and Cabrera, 2005). Each class 
and individual type of sclerosant within the same class produce this effect in different 
ways associated with diverse and highly variable patterns of efficacy, potency, and 
complications (Artemi, 2007). According to their potency, sclerosing agents can be 
classified as major (alcohol, iodine, sodium tetradecyl sulfate), intermediate (sodium 
salicylate, POL), or minor (chromated glycerin). 
Modern sclerotherapy is performed using sclerosing detergents such as POL. With their 
introduction in the 1920s and 1930s, detergent sclerosants, also known as fatty acids and 
fatty alcohols, soon became and are still the most popular sclerosant types used worldwide 
for the treatment of varicose veins. Detergent sclerosants, with increasingly favorable risk-
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to-benefit ratios, rapidly replaced older sclerosants thought to be ineffective if they could 
not produce tissue necrosis or significant thrombosis at vasodestructive concentrations. 
After intravenous injection, liquid detergent sclerosants become protein bound and 
inactivated when mixed with blood. When the foam sclerosant is injected it fills the vein 
completely; it also displaces blood from the vein and ensures that all endothelium is 
exposed to the sclerosant agent and destroyed. 
Medical observations prove that foam sclerotherapy is preferable instead of the use of liquid 
sclerosing substances (Ouvry et al., 2008). Detergent-like sclerosing agents can be 
transformed into fine-bubbled foam by special techniques. Orbach was the first who 
described the use of froth in sclerotherapy (Orbach, 1950). In 1997 new methods of 
transforming the sclerosing liquid into foam were proposed (Cabrera et al., 1997a, 1997b; 
Henriet, 1997; Monfreux, 1997) and Cavezzi and Frullini in 1999 reported their 13 month 
experience of duplex-guided sclerotherapy with sclerosing foam prepared by Monfreux’s 
method (Cavezzi and Frullini, 1999). Sadoun and Benigni (Sadoun and Benigni, 1998) and 
Garcia-Mingo (Garcia-Mingo, 1999) suggested new ways of manufacturing sclerosing foam. 
In December 1999 Tessari described a safe and easy method to generate a fairly stable and 
compact foam (made of a mixture of micro-bubbles of detergent drug and air) using two 
plastic syringes and a three-way tap (Tessari, 2000). Subsequently Frullini (Frullini, 2000) 
and Gachet (Gachet, 2001) suggested other ways to produce a sclerosing foam. The ability to 
be agitated and foamed increases the potency of detergents from 2 to 4 times by 
mechanically displacing blood and thus maximizing the surface area and the contact time  
with the endothelium. This process has the advantage of using small and presumably less 
allergenic or less tissue-toxic concentrations and volumes of sclerosant, although greater 
risks may occur if foam passes in the ocular or cerebral circulation (Duffy, 2010). 
The precise procedure to prepare the microfoam is the subject of a confidential agreement 
with a third party who is the proprietary. It is, however, based on the procedure described 
in granted European and US patents EP 656 203 and US 5 676 962, respectively (Cabrera and 
Cabrera Jr., 1997b). The Polidocanol microfoam produced by Provensis has successfully 
undergone phase III clinical trials in Europe and is currently in the process of obtaining 
approval from the Food and Drug Administration (BTG International Ltd., 2011; Redondo 
and Cabrera, 2005). 
Dermatologic application of laser technology was initiated by Leon Goldman. His work was 
further elucidated by some authors (Anderson and Parrish, 1983), who described the 
principle of selective photothermolysis. The application of this principle shows how laser 
energy is preferentially absorbed by the intended target tissue or chromophore, resulting in 
their controlled destruction while minimizing collateral thermal damage to surrounding 
normal tissue. To achieve selective photothermolysis, a wavelength that is preferentially 
absorbed by the intended target tissue (in our case the vein tissue) or chromophore is 
selected. The pulse duration of the irradiating beam is also important for selectivity. If the 
pulse duration is too long, heat absorbed by the veins will diffuse out in the surrounding 
tissues so that the veins will be not selectively heated to the necessary degree in order to be 
destroyed. If the pulse duration is too short, the light absorbing chemical species such as 
hemoglobin in blood will be heated causing vaporization. This effect can cause purpura. 
Theory dictates that the proper pulse width should match the thermal diffuse time of the 
targeted structure. For smaller vessels, for example, this thermal diffusion time can be of the 
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order of hundreds of microseconds to several milliseconds, while for larger leg veins it 
could be 5-100 ms. 
In the last decade, the treatment technique has been improved so that predictable, 
reproducible results can be achieved. Several investigations (Mordon et al., 2003) have 
enabled us to better understand the role played by the transformation of oxyhemoglobin 
(OxiHb) into methemoglobin (MetHb) in order to obtain a more marked, more selective 
laser light-blood chromophore interaction. 
Long-pulsed (as mentioned above) Nd:YAG lasers offer great advantages for treating 
varicose veins of the lower limbs. They can penetrate to a depth of 4 to 6 mm and may be 
used to treat more deeply seated vessels (Rogachefsky et al., 2002; Ross and Domankevitz, 
2005). Also, they are less absorbed by melanin (which means that Nd:YAG lasers can be 
used to treat dark phototypes). On the other hand, in order to produce penetration, high 
fluence is required and hence treatment is painful and requires cooling and even topical 
anaesthesia (Anderson and Parrish, 1983). 
The light absorption of whole blood is different depending on the osmolarity, hematocrit, 
hemodynamics and red cell morphology variables. The MetHb and protoporphyrin IX 
(PpIX) have an absorption coefficient at 1,064 nm four times greater than Hb. It is shown 
that one pulse of the Nd:YAG laser causes substantial transformation of Hb into MetHb, 
followed by a drastic decrease in blood circulation speed (Mordon et al., 2003). Then, a 
second Nd:YAG laser pulse, shortly after the first one, would be four times more effective. 
Following this theory, a system was manufactured with two different lasers built into the 
same console. The energy of the two lasers is sequentially pulsed. First, a pulse of a dye laser 
emitted at 585 nm produces an increase in the rate of intraerythrocytic MetHb, changing the 
coefficient of absorption of the Nd:YAG laser beam which is delivered after the first 
sequence. The long pulse emitted by the  1,064 nm Nd:YAG laser induces vessel damage at 
lower fluence. In reality, the pulsed dye laser has low penetration and so its efficiency is 
limited to the most superficial dermal plexus, since the vessels located at a greater depth 
than 1.5 mm are not reached by these laser pulses. Hence, significant rates of MetHb cannot 
be formed in the deepest veins (Trelles et al., 2010). 
Clinical experimental results have proved that the exposure of tissues impregnated with 
POL to laser radiation emitted at 1.06 Ǎm improves the efficacy of the treatment (Moreno 
Moraga, n.d.; Trelles et al., 2011). It combines the effect of sclerotherpy with that of the laser 
therapy and more than this, with the capabilities of drug induced modifications following 
the exposure to the laser radiation. Sometimes, the exposure of a medicine to laser radiation 
yields a product that is more biologically active than the un-exposed parent (Pascu et al., 
2011; Wainwright, 2008).  
In this respect, the data reported in this chapter represent a step to better understand the 
interaction of POL with the target tissues in the context of its exposure to pulsed laser beams 
emitted at 1,064 nm by the Nd:YAG laser.  
2. Description of Polidocanol 
Detergent sclerosants produce endothelial damage by multiple mechanisms associated with 
a decrease in endothelial cell surface tension, interference with cell surface lipids, disruption 
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of intercellular cement and extraction of cell surface proteins. Detergents are most effective 
in the form of micelles (molecular aggregates) drawn in Fig. 1.  
 
Fig. 1. Scheme of a micelle 
At low concentrations and temperatures most detergent molecules are individually 
dissolved in solution, micelles are not formed and toxicity to endothelium is considered 
minimal. By increasing sclerosant concentrations at temperatures encountered in living 
tissue, a predictable threshold for endothelial damage occurs with a commensurate increase 
in sclerosing potency. The degree of damage can be controlled varying the detergent 
concentration and the time length of the sclerosant contact with the vessel wall. 
Unfortunately, due to the dilution with blood, it is not possible to  determine the quantity of 
the sclerosing agent in intimate contact with the endothelial surface and the quantity which 
remains in circulation. Thus, the effects obtained are not always in direct proportion to their 
concentration; ‘‘downstream’’ effects with unintended damage to interconnecting vessels 
can always occur (Duffy, 2010). 
2.1 Introduction of the compound 
Polidocanol or Lauromacrogol 400, C14H30O2 (CID 24750, molecular weight 230.3868 
[g/mol]), is the pharmaceutical active ingredient of commercially available drugs listed in 
Table 1. It is a polyethylene glycol ether of Lauryl alcohol, where the average value of 
polymer is 9 (PubChem, 2011). This chemical compound is a viscous liquid at room 
temperature, having a melting point of 15–21°C. It is miscible in water, has a pH of 6.0–8.0 
and has a density of 0.97 g/cm3 at room temperature, closed to that of the  water. 
The 3D image of this molecule is shown in Fig. 2, where the carbon atoms are in dark grey 
colour, the hydrogen atoms are light grey and the oxygen atoms are red.  
Polidocanol laurel macro gel 400 laureth-9 was first synthesized in 1936 and marketed as a 
topical and local anesthetic under the trade name SCH-600 (Chemische Fabrik Kreussler & 
Co. GmbH, Germany). This urethane local anesthetic differs from classic ester and amide 
anesthetic agents because it lacks an aromatic ring.  
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Fig. 2. 3D image of Polidocanol molecule, where the carbon atoms are figured in dark grey, 
the hydrogen atoms are light grey and the oxygen are in red color. 
It is used as a topical anesthetic in ointments and lotions for skin irritation, burns, and insect 
bites and as an epidural anesthetic. The ability of POL to sclerose blood vessels without 
significant damage to surrounding tissues led to its use as a sclerosant in the 1960s. By 1967, 
it was registered in the Federal Republic of Germany as Aethoxysklerol, and it is now the 
only sclerosant approved for use in Germany (Duffy, 2010). Today, the leading 
sclerotherapy treatment in Europe is based on Aethoxysklerol. It is the only sclerosant 
approved by the Japanese Ministry of Health, Labor and Welfare (Eckmann, 2009). Recently 
- March 2010, the U.S. Food and Drug Administration approved Asclera (POL) injection 
(produced by Chemische Fabrik Kreussler & Co. GmbH, Germany, too) for the treatment of 
varicose veins in USA (U.S. Department of Health & Human Services, FDA., 2010).  
In Table 1 are synthesized the main pharmaceutical companies, researchers, developers, 
manufacturers, distributors and suppliers to provide POL. 
 
Companies Product name 
  Chemische Fabrik Kreussler & Co., Germany Aethoxysklerol, Asclera(USA) 
  Berlin Pharmaceutical Industry, Germany Aethoxysklerol 
  Cem Farma Ilac, Turkey Aethoxysklerol 
  Codali, Belgium Aethoxysklerol 
  Felo, Denmark Aethoxysklerol 
  Globopharm, Switzerland Aethoxysklerol 
  IBI International, Czech Republic Aethoxysklerol 
 Institute of Pharmaceutical Research and Technology, 
Grece 
Aethoxysklerol 
  Inverdia, Sweden Aethoxysklerol 
  Lomapharm Rudolf Lohmann, Germany Aethoxysklerol 
  Nycomed, Switzerland Aethoxysklerol 
  Repharma, Azerbaijan Aethoxysklerol 
Resinag, Switzerland Sclerovein 
  Sigma-Tau, Italy Aethoxysklerol 
  Tamro Distribution, Sweden Aethoxysklerol 
Table 1. The main pharmaceutical companies, researchers, developers, manufacturers, 
distributors and suppliers of POL 
POL should be stored at room temperature (15–250C). No special precautions are necessary 
when disposing of this material. POL at concentrations of 0.5% to 1% is stable for 3 years 
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and should be stored between 150C and 300C (59–860F). There are no special precautions for 
the disposal of unused POL (product insert). 
The common pharmaceutical presentation form of Aethoxysklerol is as ampoule of 2ml 
injection solution whose composition is given in Table 2. 
 
Composition of injected solution in 
concentration of: 
0.5% 2% 3% 
Lauromacrogol 400 (active) 10mg 40mg 60mg 
Ethanol (inactive) 0.10ml 0.10ml 0.10ml 
Pure water (inactive) 2ml 2ml 2ml 
Sodium hydrogen phosphate (buffer - inactive) 
Potassium dihydrogen phosphate (buffer - inactive) 
Table 2. Composition of Aethoxysklerol injected solution 
2.2 Mechanism of the sclerosing action 
Polidocanol exerts its sclerosant effects by causing concentration dependent differential cell 
injury (Eckmann and Kobayashi, 2005). Cellular calcium signaling and nitric oxide 
pathways become activated by the administration of the sclerosant, followed by cell death. 
The timing of endothelial cell death is predictable based on sclerosant concentration during 
exposure. This ultimately results in endothelial cell lysis but that can potentially also involve 
erythrocytes, platelets, and lead to platelet-derived microparticle formation (Parsi et al., 
2008). Although hemolysis occurs experimentally in whole blood samples at Polidocanol 
concentrations greater than 0.45%, erythrocyte lysis, platelet lysis and platelet-derived 
microparticle formation have not been a significant concern reported in any clinical trials of 
sclerosant therapy. 
2.3 Pharmacokinetics 
POL: 12 hours after intravenous application, about 90% of the POL administered would 
have been eliminated from the blood. No accumulation is to be expected even after repeated 
doses at intervals which are normally used for sclerotherapy.  
In a study made by Artemi and reported in 2007, the following values were determined after 
a single intravenous dose: protein binding 64%, terminal elimination half-life 4 hours, 
volume of distribution 24.5 l, total clearance 11.7 l/h, renal clearance 2.43 l/h and biliary 
clearance 3.14 l/h.  
Ethanol: No data are available for the level of the ethanol absorption rate. The volume of 
distribution of ethanol is 0.68 l/kg for a man and 0.55 l/kg for a woman, and is reached very 
quickly. Ethanol enters the foetus and mother’s milk. Ethyl alcohol is oxidised by alcohol 
dehydrogenase in the liver to form acetaldehyde, and acetaldehyde is in turn broken down 
by acetaldehyde dehydrogenase to form acetic acid. This metabolic breakdown method 
accounts for 90-96% in man. The rate of elimination is independent of concentration and is 
0.1 g/kg/h for a man and 0.085 g/kg/h for a woman (hourly breakdown c. 0.15‰). 
Insignificant amounts are eliminated via the lungs (2-3%) and kidneys (1-2%). 
www.intechopen.com
 Nd YAG Laser 
 
230 
2.4 Foaming process  
There are many works providing good results about the use of POL foam sclerotherapy 
(Alos et al., 2006; Cabrera et al., 2000; Cavezzi and Frullini, 1999; Frullini, 2000; Gachet, 2001; 
Garcia-Mingo, 1999; Hsu and Weiss, 2003; Ouvry et al., 2008; Rabe et al., 2008; Redondo and 
Cabrera, 2005; Santos, 2008; Tessari, 2000). The ability to be agitated and foamed increases 
the potency of detergents from 2 to 4 times by mechanically displacing blood and thus 
maximizing surface area and time in contact with endothelium. This process has the 
advantage of using small and presumably less allergenic or less tissue-toxic concentrations 
and volumes of sclerosant, although greater risks may occur if foam passes in the ocular or 
cerebral circulation (Duffy, 2010). Since foam displaces the intravascular blood and is not 
diluted in it, as in the case of liquid sclerosant injection, the concentration of the sclerosing 
agent in the vessel is known and controlled. Foam instillation leads to a homogeneous 
distribution of the sclerosant within the vessel lumen, except in very large veins where 
gravitational effects maintain better contact between the upper venous wall and the foam, 
which is far less dense than blood. Foam can be produced to be sufficiently stable from 
breakdown so being possible to provide adequate therapeutic effects from relatively short 
times in which it is kept in contact with the lumenal surface of the vein, as reported (Rao 
and Goldman, 2005). 
Generally, the sclerosing foam is defined as a mixture of gas and liquid sclerosing solution 
with tension-active properties. Besides being composed of different specific ingredients, 
foams can differ in their internal cohesion, which is related to the size of the air bubbles. 
Macrofoam contains bubbles larger than 500 µm, minifoam contains bubbles between (250 – 
500) µm, and microfoam is composed of bubbles smaller than 250 µm (Frullini, 2011; Hsu 
and Weiss, 2003). 
A given volume of liquid can be used to produce 4 or 5 times its volume in foam, depending 
on the utilized foaming method. This volume allows the use of a lower total dose of the 
sclerosant to achieve the desired effect. Sclerosing foam is characterized by variables such 
as: the type and concentration of the tension-active sclerosing agent, the gas type, the liquid-
to-gas ratio, the preparation conditions (temperature, pH), the time between preparation 
and use, and the bubble size. 
The foam homogeneity is an important prerequisite for its flow behavior (viscosity) and 
stability. The ideal foam would have uniform bubble diameter and inner gas pressure. The 
durability of foam is related to the bubble size, the tension-activity (surface tension 
properties) of the liquid solution and the conditions under which the foam is formed and 
kept. Foam should be sufficiently durable to avoid its separation into gas and liquid 
components during injection but sufficiently ephemeral to break down once injected. The 
gas must be physiologically tolerated at therapeutic doses. The mean bubble size of the foam 
should be considerably less than 100 µm (Redondo and Cabrera, 2005). 
There are many methods and mechanisms that have been applied to mix and agitate liquid 
sclerosants with gas admissions to create foams for clinical use. With the exception of one 
self-contained formulation, POL microfoam for endovenous use (Varisolve®), foamed 
sclerosants are typically produced by cyclical mechanical agitation of the liquid agent in the 
presence of a gas to generate the froth used for intravascular injection. Such “home made” 
foams commonly employ ratios of gas to liquid ranging from 1:1 to 8:1, producing foams of 
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varying densities and rheological properties. In any event, the result is a froth containing 
79% nitrogen and 21% oxygen and having a characteristic wide bubble size distribution 
(Cavezzi and Tessari, 2009). 
Orbach was the first who described the use of froth in sclerotherapy (Orbach, 1950). After 
1995 new methods of transforming the sclerosing liquid into foam were described (Cabrera 
et al., 1997a; Cavezzi and Frullini, 1999; Garcia-Mingo, 1999; Henriet, 1997; Monfreux, 1997; 
Sadoun and Benigni, 1998). In December 1999 Tessari described a safe and easy method to 
generate a fairly stable and compact foam (made of micro-bubbles of detergent drug and 
air) using two plastic syringes and a three-way tap (Tessari, 2000). Nowadays this is the 
main method used in foam sclerotherapy. Subsequently, Frullini and Gachet suggested 
other ways to produce sclerosing foam (Frullini, 2000; Gachet, 2001). 
In the Monfreux technique, negative pressure is generated by drawing back the plunger of a 
glass syringe, the tip of which is tightly closed. The resulting influx of air produces large-
bubbled, fairly fluid foam. In the Tessari technique, the turbulent mixture of liquid and air 
in two syringes connected using a three-way stopcock produces the foam. It is fine-bubbled 
and fluid at low concentrations and rather viscous at high concentrations. The mixing ratio 
for sclerosant to air is 1:3 to 1:4. The double syringe system technique involves the turbulent 
mixing of POL with air in a sclerosant to air ratio of 1:4 in two syringes linked using a 
connector. The resulting product is a fine-bubbled, viscous foam (Rabe and Pannier, 2010). 
Some authors described in 2008 a method to obtain standardized POL foam prepared by 
using the EASY-FOAM® kit (two 10 ml silicone-reduced syringes, connected by a two-way 
valve connector, with one syringe prefilled with 7.4 ml sterile air (Laboratoire Kreussler 
Pharma, Paris, France). After aspiration of 1.6 ml POL into the other syringe (1:5.6) 
standardized movements of the syringe plungers were achieved by using the Turbofoam® 
machine, with a controlled number of movements, speed, and power (Hamel-Desnos et al., 
2005; Rabe et al., 2008). 
Lately, BTG International (United Kingdom) has developed Varisolve® (polidocanol 
endovenous microfoam, PEM) as a first line treatment for incompetent great saphenous 
veins (GSV) and associated varicosities, above and below the knee and for use alongside 
endovenous thermal ablation. PEM has a controlled density, consistent bubble sizes, and 
proprietary gas mix that make it a simple and comprehensive treatment for symptomatic 
and aesthetic varicose veins.  
PEM is a pharmaceutical form of micro-foam that emulates the foam originally produced 
and studied by Cabrera (Cabrera et al., 2000, 2003, 2004) in a standardized way. It is 
generated and dispensed using a pressurized canister mechanism depicted in Fig. 3.  
An European Phase III clinical trial showed that 90% of patients treated with PEM had no 
reflux in the GSV at 3 months and fewer than 10% of patients had recurrence at 1 year. 
Patients can generally return to work or their usual activities the same day they are treated, 
and cosmetic results after PEM treatment are apparent at 6 weeks. PEM is progressing 
through three US Phase III trials to explore its safety and efficacy as a treatment for 
moderate to severe varicose veins. All studies are expected to be completed by the end of 
2011 and potential approval in 2013 (BTG International Ltd., 2011). 
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The system contains the liquid agent and a gas mixture of oxygen and carbon dioxide with 
only trace (0.01–0.08%) nitrogen present. Passage of the gas and liquid under pressure 
through a microfoam producing system yields micro-structurally consistent 1% POL 
microfoam having reproducible rheological properties. The bubble size for Varisolve® foam 
is appreciably smaller than that resulting from manual foam production techniques, and the 
absence of nitrogen facilitates more rapid absorption of bubbles within the body. Both these 
considerations are important to the safety profile, given the possibility for gas embolism to 
occur with any type of foam sclerosant therapy (Eckmann, 2009). 
 
Fig. 3. The Varisolve® PEM generation and dispensing canister. 
3. Laser sources description 
For laboratory measurements regarding the photophysical properties of POL, we used a Q-
switched Nd:YAG laser, while for clinical applications long pulsed laser types with the same 
active medium were employed. 
The difference between the two types of lasers is the fact that for long pulsed medical lasers 
the emission of the laser resonator is obtained from a simple laser cavity where elements 
characteristic to Q-switch mode are not present. In this way the laser pulse duration is given 
by the long life time of the upper laser level (of the order of milliseconds) and lamps 
emission modulation. 
Our Q-switched laser is a Continuum Surelite II. The head of the laser consists in a 115 
mm length rod of Nd3+ doped YAG pumped by a linear flash lamp. The high pumping 
efficiency is achieved through a closed coupled configuration surrounded by a high 
brilliance magnesium oxide diffuser. The flashlamps have Xe as discharge gas with a 
pressure of (1-3) atm. 
The active Q-switch is performed by the combination of a polarizer, Pockels cell and /4 
waveplate. The Q-switch allows the accumulation of high energy in the laser resonator till it 
opens and allows the cavity to oscillate. By this, fast and high peak power laser pulses are 
www.intechopen.com
Applications of Polidocanol in Varicose Vein  
Treatment Assisted by Exposure to Nd:YAG Laser Radiation 
 
233 
produced. The typical laser pulses at 1,064 nm emission wavelength for our Surelite system 
have 5 ns pulse duration, 10 Hz repetition rate, and maximum peak energy of 685 mJ. 
The fundamental laser beam emitted at 1,064 nm can be doubled, tripled, and quadrupled 
by using high harmonic generation BBO crystals. The characteristics of the beams obtained 
are: 532 nm, maximum energy per pulse 340 mJ; 355 nm, maximum energy per pulse 180 mJ; 
266 nm, maximum energy per pulse 120 mJ. 
The Nd:YAG lasers used for medical applications in leg veins treatment are long pulsed 
lasers, not having a Q-switch operation. Two different commercially available, long-pulsed 
1,064 nm Nd:YAG laser systems were engaged for the clinical results presented here, 
namely: 
 The Laserscope Lyra “i” (Laserscope, San Jose, CA, USA). To protect the epidermis 
from any adverse effects, Lyra-i system combines the long available wavelength with a 
unique flat beam profile to maximize patient safety and efficacy. The patients are 
protected by continuous parallel contact cooling that protects the epidermis. The 
cooling is carried out with a continuous flow of air (Zimmer Cryo 5® system, Zimmer 
Elektromedizin, Neu Ulm, Germany). The depth of penetration for 1,064 nm is due to 
its low scattering and epidermal transparency allowing the effective delivery of energy 
to deeply seated targets, such as blue and purple vessels while safely avoiding 
epidermal pigment. Computer adjusted fluence, delivered in adjustable pulse widths 
coupled with 1 mm to 5 mm continuously adjustable spot size is ideal for treating 
vessels from 0.5 mm to 4 mm.  
The adjustable spot size and laser fluence allow the appropriate treatment procedure for 
several classes of veins. A spot size of 2 mm and fluence of 200 J/cm2 are selected for 
spider (class I) and reticular (class II) veins, while 5 mm and 60 J/cm2 are the laser system 
parameters for truncal veins (class III) treatment. The pulses delivered are 25 to 35 ms at a 
frequency of 5 Hz, for class I and II varicose veins, and 70 ms and 2 Hz, for class III 
varicose veins. 
 A CoolTouch Varia® (CoolTouch Inc., Roseville, CA, USA) laser which has an 
adjustable pulsed cryogen cooling. The system is foreseen with an attached gas cooling 
canister that enables cooling the epidermis before and after laser pulses, at the same 
time interval between pulses. The thermal feedback is performed by precisely 
adjustment of the laser power to safely reach target temperature. Fluences used are 
similar, except for class I and II veins for which less than 150 J/cm2 are programmed 
due to the fact that the minimum spot size is 3 mm and not 2 mm as in the Laserscope 
Lyra “i” system.  
3.1 Laser tissue interaction 
Basic requirements for a laser or a light source to treat leg veins are a wavelength that is 
proportionately better absorbed by the target (hemoglobin) than surrounding chromophores 
and penetration to the full depth of the target blood vessel. Sufficient energy must be 
delivered to damage the vessel without damaging the overlying skin, and this must be 
delivered over an exposure time long enough to slowly coagulate the vessel and its lining 
without damaging surrounding tissue.  
www.intechopen.com
 Nd YAG Laser 
 
234 
Usually, optical radiation in the near-infrared wavelength range (from about 700 - 2,000 nm) 
is used, though when appropriate chromophores are available, visible wavelengths (e.g. 
green) can also be used. Photons launched into tissue are submitted to at least four optical 
processes: refraction, scattering, absorption, or output from the tissue.  
In the context of this chapter, the light scattering in the tissues plays an important role since 
it regulates in a sense the penetration depth of the laser radiation in the tissue. There are 
different types of light scattering which may be produced in a tissue by its components, 
such as the Rayleigh scattering produced by very small particles, the Gans and Debye 
scattering produced by spherical and cylindrical macromolecules, globular proteins etc. 
(Grossweiner, 2005). Actually, the presence in the tissue of macromolecules, cells, 
water/liquid volumes, structures that have constituent layers (such as veins and arteries, 
cornea) enhance the light scattering within the tissue.   
When photons are absorbed, the energy from the photon is converted into inter- and intra-
molecular energy and results in generation of heat within the tissue. At the same time the 
good absorption in tissue limits the size of the lesion created by the laser irradiation. So, a 
compromise between good penetration and good absorption has to be found. After the 
initial absorption the temperature generated spreads through the tissue and enlarges the 
lesion somewhat, depending on the perfusion of the tissue. Large vessels will transport the 
heat away from the site and the effectively achieved temperature is reduced. For vascular 
structures the thermal relaxation time is of the order of milliseconds, so that lasers with 
pulse durations less than 1 ms are likely to produce little thermal injury. 
Following Altshuler’s expanded theory of selective photothermolysis, the chromophore is 
the Hb of the circulating blood. This captures the laser energy and turns it into heat. The 
chromophore must heat up sufficiently for thermal damage to occur in the vessel and 
especially on the vascular wall (Altshuler et al., 2001). The chromophore must heat intensely 
enough for heat to propagate to the wall of the vessel, but not to the extent that this becomes 
carbonized, which would involve the end of heat transfer in the vein structure. These data 
are highly important when deciding upon laser pulse dosimetry. 
When the parameters (fluence and pulse width) are well chosen, intraparietal bleeding 
and rupture of the elastic fibers of the vein wall are observed immediately. Then, 
eosinophil appears in the muscle fibers of the treated vein. With the appropriate histology 
staining, there is a notable increase in the presence of beta-2-type tissue growth factor 
(TGF-beta 2). This intermediary acts on the fibroblasts increasing the secretion of proteins 
in response to thermal damage (heat shock protein 70), which are responsible for 
accelerating collagen and elastin fiber synthesis in the rough endoplasmic reticulum of the 
fibroblast (Black and Barton, 2004; Sadick et al., 2001). The first sequence is to induce 
vessel fibrosis and its re-absorption. 
Optical absorption in the near-infrared spectral range is generally due to combination of 
overtone bands of fundamental molecular stretches. For wavelengths near 1,000 nm, water 
is a primary absorber of optical energy. 
The choice of wavelength and pulse duration is related to the type and the size of the target 
vessel. Deeper vessels require a longer wavelength to allow penetration to their depth. Pulse 
duration must be matched to vessel size; the larger the vessel diameter, the longer the pulse 
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duration required to effectively damage the vessel thermally. To be most effective, thermal 
injury must encompass the full thickness and circumference of the vein wall endothelium, 
rather than just the most superficial aspect of the vein wall. The relative importance of the 
hemoglobin absorption peaks in green (541 nm) and red to infrared (800-1,000 nm) shifts as 
the depth and the size of the blood vessel changes. Absorption by hemoglobin in the long-
visible to near-infrared range appears to become more important for vessels more than 0.5 
mm in diameter and at least 0.5 mm below the skin surface. 
This approach of using pulsed lasers to limit thermal effects can also be used to ablate tissue. 
The limiting pulse length would be determined by the thermal relaxation time of the 
material. This is the time for heat to diffuse out of the irradiated volume and it is determined 
by the thermal diffusivity of the tissue and the dimensions of the volume. When laser 
energy is deposited in pulses shorter than the thermal relaxation time, heat accumulates and 
high temperatures are achieved. The ablative event can then occur before the heat diffuses 
out of irradiated volume. This confinement of heat can reduce the thermal damage incurred 
by adjacent tissue.  
4. Experimental devices 
First of all, we measured the optical properties of Aethoxysklerol 2% (Chemische Fabrik 
Kreussler & Co., Germany) solution. The absorption spectra measurements in 
spectrophotometer cells of 10 mm optical length are performed in UV-VIS-NIR spectral 
ranges using a Perkin Elmer Lambda 950 spectrophotometer (PerkinElmer, Massachusetts, 
USA) that has UV/VIS resolution ≤ 0.05 nm, NIR resolution ≤ 0.20 nm, with an error limit 
for absorbance of ± 0.004 %. This high-performance spectrophotometer features a double 
beam, double monocromator and ratio-recording optical system. As for the IR spectral range 
we used a FTIR Spectrophotometer Nicolet Magna 550 (Nicolet Instruments Inc., Madison, 
USA), working at (4000 – 400) cm-1 spectral domain and resolution 0.125 cm-1. 
Secondly, we exposed medicine solution samples to laser radiation in order to detect the 
possible molecular modifications induced in drug by the laser beam. The irradiation 
experimental set-up is shown in Fig. 4. We exposed Aethoxysklerol solution samples at laser 
beam emitted by a pulsed Nd:YAG laser (Continuum, Santa Clara, USA,, Excel Technology, 
Surelite II Frequency 10 Hz, FTW 5 ns) at 1.06 Ǎm, the laser radiation having the following 
characteristics: repetition rate 10 pps, beam energy on the sample 50 mJ.  
The exposure time was made on samples in bulk, between 2 min and 30 min; the sample 
was introduced in spectrophotometer cells of 10 mm (C – Fig. 4) and the corresponding 
irradiation dose varied from 60 J/cm2 to respectively 900 J/cm2; 8-10 % of the laser radiation 
was directed through a beam splitter (BS) unto a powermeter (P).  
The effect of the laser light may be enhanced if the POL is used as foam since the light 
scattering in the tissue becomes more important and the effective absorption of the laser 
beam becomes larger. So, one might have in this case a larger number of modified POL 
molecules and/or a larger volume of tissue which is exposed to laser radiation. 
Using the Tessari method - two disposable 5 ml syringes (Luer Slip) connected to a three-
way stopcock, we produced foam from a mixture of Aethoxysklerol solution and 
atmospheric air; the mixture ratio was 1:4 (Fig. 5). This batch was passed between the two 
syringes about 40 times and the resulting hand-made foam was stable for 5-6 min. 
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Fig. 4. Experimental set-up for laser irradiation of POL samples (P- powermeter, C- sample 
cell, BS- beam splitter) 
     
                           (a)                                                       (b) 
Fig. 5. The Tessari foaming method (a) and foam consistency (b) 
Foam and solution samples of POL were investigated by Raman spectroscopy as shown in 
the experimental set-up in Fig. 6. The laser radiation used to excite the Raman emission is 
the second harmonic of the same pulsed Nd:YAG laser emitting pulsed radiation at  10 Hz 
repetition rate,  pulse duration 5 ns, and 250 mJ energy at 532 nm. The complete description 
of the laser source was made in Section 5. The detection and analysis of Raman signal are 
made by a spectrograph (SpectraPro 2750, Acton Research) and ICCD camera (PI-MAX 
1024RB, Princeton Instruments).  
The SpectraPro 2750 is a 750-mm, f/9.7-aperture, triple-grating monochromator/ 
spectrograph that features a versatile multiport optical system, 0.0025 nm drive-step size, 
built-in computer compatibility, and a wide scanning mechanical range up to 1,400 nm). As 
a monochromator, it offers built-in stepping-motor scanning and 0.023 nm resolution, plus 
easy integration into automated spectral-data acquisition systems. As a spectrograph, the 
SpectraPro 750 provides 1.1 nm/mm dispersion, a large 14 mm high by 27 mm wide focal 
plane, and interchangeable triple grating turrets. The grating types are as follows: 
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holographic UV, 2,400 lines/mm, for (185-375) nm; holographic VIS, 2,400 lines/mm, for 
(300-800) nm, blaze 1 µm and 600 lines/mm, for (650-1,500) nm. 
 
Fig. 6. The Raman spectroscopy system 
The PI-MAX 1024RB from Princeton Instruments is a high performance intensified camera 
system featuring a spectroscopy format CCD. The imaging array is 1,024 x 256 and the 
spectral range (185-900) nm. It is fiber optically coupled to Gen II intensifiers with wide 
spectral coverage, quantum efficiency between (10-30)% in spectral range (200- 550) nm and 
54 to 64 lp/mm resolution. Sub-nanosecond gating capability and an integrated 
programmable timing generator (PTG) make these ICCD cameras suitable for time-resolved 
spectroscopy applications. 
5. Target patients groups and specific materials and method 
From the clinical point of view and to illustrate this chapter we present the evaluation of  leg 
telangiectasias and reticular veins (classes I to III) which were treated with the Nd:YAG 
laser following POL micro-foam injections. From our large casuistry we have selected a 
representative sample that underwent a prolonged control and follow-up.  
Materials and method 
This review corresponds to 200 patients, ages from 21 to 76 years (mean 37.2 y.o.a), treated 
with POL and Nd:YAG laser (Table 3). All patients were followed up and assessed 
periodically up to two years after treatment. Permission was granted to check medical files 
from the Administrative Council of the Instituto Médico Láser, Vilafortuny. The patients 
were females presenting leg varicosities that were treated with the same protocol. No 
patient has been exposed to sunlight or artificial tanning with UV-B during the 2 months 
prior to treatment; neither had they used any oral contraceptives for at least 12 weeks before 
the treatment. Exclusion criteria included: patients less than 18 years of age, pregnant 
women, lactation, scars or skin infections in the treatment area, the use of anticoagulants, a 
history of photosensitivity, keloids and/or hypertrophic scars and repeated herpes 
infections. None of the patients has been previously treated with laser for varicose veins. 
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60 patients suffered red venulectasias of less than 0.5 mm in diameter (class I); 72 of blue 
venulectasias of 0.5 to 1.5 mm (class II), and 68 patients had reticular veins 2 to 4 mm in 
diameter (class III).  
 
 
CLASS I VEINS 
Total no. pat. 60 
CLASS II VEINS 
Total no. pat. 72 
CLASS III VEINS 
Total no. pat. 68 
AGE 
20-35 years 15 6 4 
36-50 years 27 23 27 
51-over 18 43 37 
VEIN COLOR 
Red 41 39 12 
Blue 6 5 42 
Red/blue 13 18 14 
Table 3. Patients demographics 
All patients signed an informed consent for treatment and prior to treatment underwent a 
Duplex Ultrasound test (Soniline 050, Siemens, Issaqua, Japan) to screen for presence of 
reflux in the deep system, saphenous axes and in the perforant veins.   
The micro-foam was obtained using two 10 ml Omnifix syringes with a Luer-Lock 
connection, a 3-way stopcock to connect the syringes and a 15G load needle with an air 
micro-filter. Two ml of POL (Aetoxysclerol® tamponné/lauromacrogol 400 (Kreussler 
Pharma, Germany) were used at 0.3% and 8 ml of air. Pumping and passing from one 
syringe to the other 15 times, produces stable micro-foam following the Tessari technique 
(Cavezzi et al., 2002; Frullini, 2000; Hamel-Desnos et al., 2003; Tessari, 2001; Tessari et al. 
2001; Wollmann, 2004). The resulting foam is rich in nitrogen, with an irregular bubble size 
and a highly internal cohesion (Redondo and Cabrera , 2005). 
The 200 patients received two treatments. The second treatment was given six weeks after 
the first.  Parameters and methodology were the same for both treatments. The laser used 
was a 1,064 nm long pulse Nd-YAG laser, Laserscope Lyra “i”™  (Laserscope, San Jose CA, 
USA). The laser had a variable spot diameter, from 1 mm to 5 mm. The laser energy per 
pulse was delivered according to the treatment program at the same time that constant 
cooling of skin surface occurred because of the glass chamber that is adapted to the tip of the 
hand piece nozzle. The coolant is constantly circulated to cool the skin. In addition, a 
continuous flow of cold air that is capable of giving up to 1,000 l/m was used.  
The device offers various programs to select the air flow. Program #5 was used which gave 
600 l/m. The nozzle was pointed, at all times towards the place where the laser beam was 
directed. The temperature of the cold air was of 4ºC. This was measured by pointing the 
thermometer under the air flow coming out of the hose nozzle. The approximate time of the 
air flow focusing on the treatment area was of one second; according to the external 
temperature detected with an IR thermometer (Laser Infrared Thermometer Center 350®, 
Center Technology Corp., Taiwan) the skin temperature was reduced to 22ºC from the basal 
temperature of 33ºC. The cooling device (Cryo 5, Zimmer Elektromedizin, Neu Ulm, 
Germany) followed the vein path treated with the laser pulses.   
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For class I and II veins, a 2 mm laser beam spot size was used, whereas for class III veins a 5 
mm beam was used. Fluences were 200 J/cm2 for class I and II and 60 J/cm2 for class III. The 
laser pulse width was 30 ms for class I and II, and 70 ms for class III with a pulse repetition 
rate of 5 Hz for class I and II and 2 Hz for class III veins. According to the utilized protocol, 
all patients received treatment of the whole limb in the same session. For this, areas of 30x30 
cm were selected continuing until the whole leg was treated. Disinfection of the areas for 
treatment was carried out using hydrogen peroxide. No anesthesia (i.e. any type of 
anesthesia) was used. Then, the POL micro-foam injection was injected using a 2 ml Omnifix 
syringe with a 30G needle. The sclerosant concentration was 0.8% in all cases and the 
maximum amount injected was 30 ml per session which proved to be enough in all cases. 
The average amount of sclerosant injected in each of the two scheduled treatments was 
around 20 ml.  
Injection caused vessels to blanch and then a delay time of (1-3) min was necessary for the 
vessels to recover a soft pink color. Following the injection, laser was applied on the whole 
length of the vessel in the 30 x 30 cm area until it was totally covered with laser pulses.  
Because the total varicosity that the leg presented were treated in one session (with a 
repetition session after six weeks), the average number of laser pulses per session varied 
from 600 to 900. 
After 6 weeks, the treatment was repeated with the same parameters. The patients returned 
for control at 18 weeks after the first treatment and the final assessment was at 2 years, 
taking as a reference the last (second) treatment carried out. At the 18-week control, 
complications were evaluated and further follow-up of their evolution was carried out at the 
2 year assessment.  
At this final assessment, all patients answered questionnaires to score in percentages their 
subjective impression regarding results. The percentages scored were: >90%, Very Good 
Results; 70 to 89%, Good Results; 50 to 59%, Fair Results and < 50%, Poor Results. Patients’ 
satisfaction (PS) was determined by adding up the Very Good and Good results. 
To objectively determine vessel clearance, photographs were taken, at a distance of 18 cm, 
using a Canon EOS 400D photo camera, equipped with a macro-lens (Tokina ATX Pro 100 
f 2.8 Macro, Sea&Sea Flash Macro DRF 14, Tokyo, Japan). Photographs were taken before 
first treatment and at 2 years after the second treatment and they were used as objective 
references for evaluation by two independent Doctors, familiar with leg vein treatment 
with laser.   
6. Physical and clinical results and discussions 
It is important to provide a thorough understanding of the basic physical principles that  
underlie the use of coherent light in therapeutic applications. In this way, with respect to the 
new method to treat the varicose veins by combining POL microfoam and pulsed 1,064 nm 
Nd:YAG laser beam we must consider three factors: the drug sclerosis abilities, the action of 
the laser beam on the surrounding tissues and the possible increasing of the drug’s potency 
under the laser light exposure. Of course, in practice it is important to adjust each of the 
parameters involved in the exposure to laser radiation in order to obtain the best results. 
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6.1 Optical results and discussions 
Lasers used for the percutaneous treatment of varicose veins of the lower limbs must fulfil 
the principles of selective photothermolysis: a wavelength that is preferably more absorbed 
by Hb than by other similar chromophores; sufficient penetration as to achieve the depth at 
which the vessel for treatment is found; the appropriate energy to damage the vessel 
without damaging the skin; and release of energy slowly so that the heat reaches the vein 
wall without damaging the adjacent tissues (Suthamjariya et al., 2004). In order to achieve 
the above, the following variables must be taken into account: laser beam spot size, fluence, 
pulse width, pulse repetition rate and the technique used to apply the treatment. 
Our laser irradiation and Raman spectroscopic measurements are made with experimental 
devices that involved time width pulses, energies, and irradiation doses that are different 
from those used in medical practice. However, they are made in order to better understand 
the physical processes specific to the interaction of the laser light with the tissues of medical 
interest in the treatment of the varicose veins.  
The light propagation in turbid biological media is jointly governed by the absorption and 
scattering properties of the medium. On the other hand, the optical properties (absorption 
and scattering of light) of the marketed sclerosing substance may be subjects for studies  in 
order to elucidate the mechanisms involved in this particular case in which combined 
sclerotherapy and light therapy of varicose veins are involved. 
The absorption spectra of the medicine, shown in Fig. 7 and Fig. 8, indicate no significant 
absorption in the UV-VIS spectral range, and very weak peaks in NIR at 900 nm, 1.06 Ǎm, 
1.19 Ǎm, 1.69 Ǎm and 1.72 Ǎm; they are the result of the superposed absorption of all the 
compounds included in the commercially available Aethoxysklerol 2%. 
 
Fig. 7. UV-VIS absorption spectrum of Aethoxysklerol 2% 
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Fig. 8. NIR absorption spectrum of Aethoxysklerol 2% 
Also, the FT-IR spectrum of POL shown in Fig. 9 is influenced by the absorption properties 
of water contained in the commercially presentation of the Aethoxysklerol solution. 
 
Fig. 9. The FT-IR spectrum of Aethoxysklerol 2% 
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The ethyl alcohol, for instance, is one of the inactive substances included in the 
commercially available Aethoxysklerol and has relatively significant absorption peaks at 
around 900 nm, 1 Ǎm and 1.2 Ǎm as it can be observed in Fig. 10. The absorbance measured 
in laboratory is in good concordance with literature reports (see Fig.10.a for recent literature 
reports). 
  
    a)            b) 
Fig. 10. The spectra of Ethanol in NIR: a) the transmission spectrum (Barun and Ivanov, 2010); 
b) the absorption spectrum (Smarandache et al., 2010)  
Also, water presents broad absorption bands in NIR and middle IR, as it is shown in Fig. 11.  
 
Fig. 11. The absorption spectrum of ultrapure water (Querry and al., 1998) 
Some authors have assumed that the molecules of drugs can be photoactivated by assisting 
the hydrolysis process that results from excitation of vibration levels of the water molecule 
in the spectral range of 1-2 Ǎm, following the absorption of infrared radiation by the water 
molecules (Fumarel et al., 2009). 
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We exposed the commercially available Aethoxysklerol 2% at laser beam emitted by a 
pulsed Nd:YAG laser at 1.06 Ǎm, between 2 min and 25 min (exposure procedure as 
shown in Fig. 4). Following the irradiation, the absorption spectra of the medicine was 
measured (Fig. 12).  
 
Fig. 12. The absorption spectra of Aethoxysklerol 2% exposed to 1.06 Ǎm Nd:YAG laser 
radiation. 
These spectra indicate that for wavelengths that exceed 500 nm they remain within the 
measuring error limits (±0.004 %). We assume that in the spectral range (1,000-1,100) nm the 
absorption is due rather to the main components of the tissue (melanin, water and 
hemoglobin/ oxihemoglobin); methemoglobin, especially, has the absorption three times 
greater than oxihemoglobin in this spectral range (Lee et al., 2006), (Fig.13). 
Derivatives of blood hemoglobin, molecular oxygen dissolved in all components of the 
biological tissue, different ferments and other tissue substances that absorb light are 
considered as primary photoacceptors. Several photoinduced processes are known to take 
place during irradiation of an organism, such as photodissociation of oxyhemoglobin and 
the light-oxygen effect (Barun and Ivanov, 2010). Both mechanisms involve the absorption of 
light and the formation of oxygen in different forms which have a biological effect. The 
efficiency of these processes depends quantitatively on the way the light propagates and on 
the absorption coefficients of individual chromophores in the tissue of interest.  
Modifications that as a trend are above the error limits are obtained in the spectral range 
(250-285) nm, as it is shown the detail in Fig. 12. In some cases (exposures at 4 min, 6 min, 8 
min) the absorption curves may be considered within the error limits of the measuring 
system but they evaluate according to the trend.  
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A possible explanation of this behavior of the curves is that nonlinear absorption effects take 
place in Aethoxysklerol, such as the absorption of 4 photons at 1.06 Ǎm, which would 
correspond to a transition at 266 nm. This modification may show that after absorbing four 
photons at 1.06 Ǎm the Polidocanol molecules change their structure. The interaction 
mechanisms of laser radiation to the investigated solution are not completely elucidated and 
it is expected that further studies give a better understanding of them. More, it is expected 
that the modified Polidocanol is more efficient in destroying the varicose veins than the 
unirradiated solution (Smarandache et al., 2010). 
 
Fig. 13. The absorption spectra of hemoglobin (Hb-R), Oxihemoglobin (Hb-O2) and 
Methemoglobin (MetHb) (Lee et al., 2006) 
In an attempt to change the chromophore to obtain significant rates of MetHb, while seeking 
to increase photon absorption, J. Moreno Moraga & all (n.d.) started the combined 
application of microfoam sclerosants, proven to be efficient for vein sclerosis, with the action 
of pulsed 1.06 µm Nd:YAG laser beams. 
The measurements performed at the National Institute for Laser, Plasma and Radiation 
Physics at Bucharest (Smarandache et al., 2011) have shown that the use of POL in the foam 
form increases the optical path of the laser radiation in the foam by light scattering, which 
leads to an increase of the total absorption, since this is proportional with the product 
between the absorption coefficient, the optical path length in the sample and the 
concentration of the absorbent. Laser energy absorption in the foam can be boosted by the 
multiplication of the impacts of the photons at the collisions with the gas bubbles. Moreover, 
under these circumstances, the number of changed POL molecules could also increase. 
Following the line of increasing the efficacy of the laser beam if the POL is used as foam 
introduced in the tissue, the foam (produced by the Tessari method and the procedure 
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described in Section 2) and solution samples of POL were investigated by Raman 
spectroscopy. The obtained Raman signals were more intense for foam than for simple 
solution samples (Fig. 14).  
 
Fig. 14. The compared Raman spectra of the Polidocanol in solution and foam presentation 
This laser light scattering enhancement is due to a longer optical path of the laser beam in 
the foam sample. The Raman vibrational lines corresponding to foam sample are more 
structured and stronger.  
Also, the Raman signals were acquired at different time moments after the preparation of 
the foam samples. The results indicate that there are some parameters which must be taken 
into account, such as the bubble dimensions referred to the foam cohesion; these are 
important with respect to the moment of exposure of the varicose vein injected before with 
foam POL and exposed in the tissue to laser radiation. As it can be seen in Fig. 15 the best 
scattering signals were obtained at 2 minutes after foam preparation, in our experimental 
conditions. After few minutes the foam is destroyed and the intensity of the characteristic 
vibrational lines decreases drastically. 
It is very important that physicians who use laser irradiation of the organism for therapeutic 
purposes and/or irradiated drugs have a physically well-founded quantitative instrument 
which would permit an analysis of the significance of the processes involved as a function of 
the spectral range of the irradiating light, its duration, and power. In addition, the 
development of a physical basis for the interaction of light with such a special object as 
biological tissue and the development of recommendations for the optimum interaction 
parameters are of fundamental scientific interest for medical applications.  
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Fig. 15. The influence of foam separation (in two phases: liquid and remaining foam) on the 
Raman spectra of a POL foam sample 
6.2 Clinical results and discussions 
Immediately after treatment, darkening of the intravascular pigmentation with perivenous 
erythema was noticed. These alterations had completely disappeared when patients came 
back after 6 weeks for the second treatment. In spite of not having used any topical 
anesthesia, tolerance to treatment was good. Out of the 200 treated patients, 6 patients did 
not show up for the 2 year assessment, i.e. 3 class I patients, and 3 class III.    
Answers to questionnaires regarding results corresponding to the 2 year assessment are 
presented in Table 4. The results correspond to scores presented by patients (subjectively) 
and those given by Doctors (objectively). Total satisfaction index (SI) was deduced by 
adding Very Good and Good scores given by patients.  So, SI  was 170 out of 194 patients, 
corresponding to 87,6% that showed up for the 2 years after assessment taking into account 
that 200 patients received treatment initially.  
 
Nº pat. 
 
Vein type 
according to 
vessel 
diameter 
PATIENT EVALUATION DOCTOR EVALUATION 
Very 
Good 
Good Fair 
Very 
Good 
Good Fair 
57 Class I 1 46 10 4 48 5 
60 Class II 17 41 2 22 37 1 
65 Class III 39 26 0 43 22 0 
Table 4. Assessment of patients at 2 years 
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At 18 weeks, hyper-pigmentation and matting were noticed in 8 patients, all of them 
presenting class I veins. However these complications have disappeared at the 2 year 
assessment. The greatest success was achieved in class II and III veins. The results obtained 
in the evaluation at week 18 remained stable even at the 2 year assessment (Fig. 16 – Fig. 18).  
 
Fig. 16. Vein Class I. Aspect before and at 2 year assessment  
 
Fig. 17. Vein class II. Before and results 2 years after POL+ laser treatment 
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Fig. 18. Vein class III. Patient before and 2 years after treatment with described technique 
The reported clinical results show that the use of POL foam combined with the exposure of 
the patient’s tissue which contains it at pulsed laser beams of 1.06 Ǎm wavelength allow 
obtaining better effects in the treatment of the varicose veins. 
7. Conclusions 
Clinical results prove that foam sclerotherapy combined with photothermolysis based on 
laser therapy increases the efficiency of the varicose veins treatment (Trelles et al., 2011). 
The foamed form of the detergent sclerosing drugs has resulted in improvements in the 
efficacy of sclerotherapy. Foam sclerotherapy reduces the dose and concentration of injected 
drug and assures a better intimate contact of the active substance with the target tissues.  
Concerning the foaming procedure, it is recommended to achieve a compromise between 
the bubbles dimension and the foam stability in time, so that the value of the surface tension 
is big enough to produce sclerosis of the target tissue and, nevertheless, the foam does not 
selfdestroys too quickly and dilutes in the blood stream before acting on the vein. 
On the other hand, pulsed Nd:YAG lasers emitting at 1,064 nm offer important advantages 
for treating varicose veins of the lower limbs. They penetrate more and are less absorbed by 
melanin, which means that they can treat dark phototypes. A laser pulse at 1,064 nm  
converts Hb into the more spherically shaped MetHb, which has a 4 times higher absorption 
coefficient. After initial irradiation, further delivering of energy is more effective at heating 
blood and the surrounding vessel (Kunishige et al., 2007). In order to produce penetration, 
high fluences are required and hence, treatment is painful and requires cooling and even 
topical anaesthesia, which are considered as disadvantages of this treatment method. 
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Comparing the spectroscopic measurements data with the clinical experimental results, we 
might conclude that the improvement of the action of Polidocanol commercially available as 
Aethoxysklerol 2% on the varicose vein by exposure of the impregnated tissues with 1.06 
Ǎm laser beam is possible due to the following mechanisms: 
 for wavelengths around 260 nm, the laser radiation may be absorbed by the Polidocanol 
proper. The mechanisms of interaction between the veins tissues and the medicine 
under the influence of laser radiation are not elucidated yet, but it is possible that 
nonlinear absorption effects take places in the tissue such as absorption of 4 photons at 
1.06 Ǎm (which would correspond to a transition at 266 nm), which may be responsible 
for further effects on the tissue; 
 at ǌ=1.06 Ǎm the absorption may be produced by the Ethyl alcohol and the main 
chromophores such as hemoglobin, especially methemoglobin and melanin; this may 
contribute to the sclerosis of the veins in the exposed area but it remains to clarify the 
possible mechanisms which lead to this effect. The modifications of the molecular 
structure of Polidocanol may be produced by the Nd:YAG laser radiation once this 
drug is introduced in the tissue.  
The effect of the laser light may be enhanced if the Polidocanol is introduced as foam since 
than, the light scattering in the tissue becomes more important and the absorption of the 
laser beam becomes larger. So, we might have in this case a larger number of modified 
Polidocanol molecules. The Raman spectroscopy measurements prove that the Raman 
signals were more intense for foam than for simple solution samples. This laser light 
scattering enhancement is due to a longer optical path of the laser beam in the foam sample. 
The vibrational lines corresponding to foam sample are more structured and stronger.  
As for the proper/most recommended moment to expose the varicose vein injected before 
with foam POL to laser radiation, the results of Raman spectroscopy study, performed at 
different moments of foam lifetime, indicate that there are some parameters which must be 
taken into account, such as bubble dimensions referred to the foam cohesion. 
As for the direct clinical application of the Polidocanol, assisted by Nd:YAG laser radiation, 
the combined treatment of leg veins with Polidocanol (micro)foam and 1,064 nm Nd:YAG 
laser pulses shows promising possibilities for coagulation of varicles of the lower limbs with 
efficacy, without the damage of the skin surface.  This kind of treatment, using low fluency, 
permits carrying out treatment sessions on larger areas with patient comfort. Efficacy may 
be substantially due to Polidocanol injection given to the patient before his/her exposure to 
laser pulses. The Polidocanol micro foam sclerosant would change the optical absorption of 
the Nd:YAG emitted at 1,064 nm, increasing the efficacy of the treatment and the vein 
closure. The obtained promising results are backed by evidence-based clinical outcome, and 
efficacy has been assessed up to 3 years (Trelles et al., 2011). 
Further studies are needed to elucidate the role of Polidocanol microfoam interaction with 
the Nd:YAG laser beam and both a possible molecular excitation and light scattering 
phenomenon that will enhance the observed results.  
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